Global pharmaceutical company Eli Lilly (NYSE: LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 55.5% year on year to $19.8 billion. The company’s full-year revenue guidance of $83.5 billion at the midpoint came in 2.1% above analysts’ estimates. Its non-GAAP profit of $8.55 per share was 25.9% above analysts’ consensus estimates.

Is now the time to buy LLY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Eli Lilly’s first quarter results received a significant positive market reaction, driven by strong revenue growth across its portfolio and notable progress in new product launches. Management credited the outperformance to the rapid uptake of obesity and diabetes therapies, especially the newly launched oral GLP-1 drug Foundayo and continued strength in Mounjaro. CEO David Ricks highlighted the acceleration in global rollout and the broadening of access programs, noting, “Foundayo has been proven highly effective for weight management, offering the benefits of GLP-1 therapy in a pill form.” Key therapeutic areas, including immunology, oncology, and neuroscience, also posted robust gains, supported by expanding indications and new patient starts.

Looking forward, Eli Lilly’s updated guidance reflects expectations that broad payer access for obesity medications, as well as continued expansion in international markets, will sustain momentum through the year. Management emphasized that the Medicare GLP-1 bridge program and the Employer Connect platform are intended to drive further uptake among seniors and working adults. CFO Lucas Montarse stated that investments in direct-to-consumer promotion and physician education will underpin brand awareness and differentiation for Foundayo, while President Livia Yuffa described upcoming commercial access milestones as “important catalysts of growth.” The company’s pipeline, including new Phase III programs and recent acquisitions, is expected to provide additional sources of growth in the near term.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to strong demand for obesity and diabetes medications, successful new product launches, and progress in expanding access for patients globally.

• Foundayo launch momentum: The oral GLP-1 medication Foundayo began its U.S. rollout with broad pharmacy distribution, early high prescriber engagement, and over 20,000 patients treated within weeks. Management sees this as a key differentiator in the obesity market, highlighting its potential for scalability and global reach.
• Mounjaro drives growth: Mounjaro, an incretin-based therapy for diabetes and obesity, continued to see strong volume-driven gains. Global revenue growth was especially pronounced in regions like China, Brazil, and Korea, where recent reimbursement wins and market share gains have accelerated adoption.
• Access expansion initiatives: The launch of Employer Connect and the extension of the Medicare GLP-1 bridge program are aimed at improving affordability and access, particularly for seniors and employees. Management noted that these programs are expected to gradually increase coverage and persistency rates throughout the year and into 2027.
• Product pipeline advancement: Multiple pipeline milestones were achieved, including positive Phase III data for key assets in oncology, immunology, and neuroscience. New Phase III program initiations and recent acquisitions (Orna Therapeutics, Syntessa, Colonia Therapeutics, Ajax Therapeutics) reflect the company’s commitment to diversifying its future growth sources.
• Patient activation and education focus: Management underscored ongoing investment in physician education, patient awareness campaigns, and direct-to-consumer advertising—especially for Foundayo and other key launches—to drive uptake and differentiate new brands in a competitive market.

Drivers of Future Performance

Eli Lilly’s full-year outlook is underpinned by expanding access to obesity therapies, international market growth, and continued investment in its clinical pipeline.

• Scaling obesity and diabetes access: The Medicare bridge program and Employer Connect are expected to increase patient access and drive incremental uptake, especially as these initiatives ramp throughout the year. Management believes that commercial and government coverage will gradually normalize obesity care, supporting growth in both self-pay and insured segments.
• International and portfolio expansion: Ongoing launches for Mounjaro and Foundayo in over 40 countries, as well as continued market share gains in emerging markets, are projected to sustain high revenue growth rates. Management also highlighted the importance of new product launches and label expansions for maintaining the company’s momentum.
• Pipeline investment and risk management: The company is investing in 42 active Phase III programs and integrating recent acquisitions to diversify its portfolio. Management noted that ongoing R&D and increased promotional spend may pressure margins, but expects strong revenue growth to offset these investments. Risks include price sensitivity in ex-U.S. markets and potential competition from generic or alternative therapies.

Catalysts in Upcoming Quarters

Looking ahead, StockStory analysts will focus on (1) the pace of adoption for Foundayo and the expansion of prescriber and patient base, (2) the progression of Medicare and Employer Connect access initiatives as they move from pilot phases to broader implementation, and (3) continued global uptake and market share trends for Mounjaro and Zepbound. Additionally, we will monitor progress on pipeline milestones and the integration of newly acquired assets for indications beyond obesity and diabetes.

Eli Lilly currently trades at $932.74, up from $851.21 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.